METHODS: We compared serum trough concentrations between subcutaneous and intravenous administration within a matched cohort (n = 50).
RESULTS: Subcutaneous administration (n = 25) was associated with lower concentrations compared to intravenous administration (n = 25) (log-B=-0.28, p = 0.01). In an exploratory group of 11 patients receiving extended interval dosing of subcutaneous natalizumab, the median trough concentration was even lower.
CONCLUSIONS: Subcutaneous natalizumab can lead to lower drug concentrations, potentially limiting extended interval dosing.
方法:我们比较了匹配队列中皮下和静脉给药之间的血清谷浓度(n=50)。
结果:与静脉给药(n=25)相比,皮下给药(n=25)与较低的浓度相关(log-B=-0.28,p=0.01)。在一组11名接受延长间隔皮下那他珠单抗给药的患者中,中位谷浓度甚至更低。
结论:皮下那他珠单抗可导致药物浓度降低,可能限制延长间隔给药。